Business Context and Reporting Period
This Form 8-K is a current report filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on June 17, 2025. The filing discloses unregistered sales of equity securities and other corporate governance events. The company is incorporated in Delaware and trades on the NASDAQ under the symbols ATNF (Common Stock) and ATNFW (Warrants).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity grants and board appointments rather than financial performance.
Material Changes
Unregistered Sales of Equity Securities (Item 3.02)
On June 17, 2025, the Board of Directors approved the grant of stock options to key personnel in consideration for services rendered. The grants were made under Section 4(a)(2) of the Securities Act of 1933 as they did not involve a public offering. The specific allocations are:
- Blair Jordan (CEO): 410,000 shares (issued to Blair Jordan Strategy and Finance Consulting Inc.)
- Ryan Smith (Lead Director): 255,000 shares
- Stephen H. Shoemaker (Director): 165,000 shares
- Dr. Lawrence Steinman (Director): 110,000 shares
- Eric R. Van Lent (Chief Accounting Officer): 25,000 shares
Total options granted: 965,000 shares. These securities are subject to transfer restrictions and appropriate legends.
Board Committee Appointments (Item 8.01)
Effective June 17, 2025, the Board made the following changes to committee leadership:
- Stephen H. Shoemaker appointed as Chairperson of the Audit Committee (succeeding Ryan Smith) and added as a member of the Compensation and Nominating and Corporate Governance Committees.
- Ryan Smith appointed as Chairman of the Compensation Committee (moving from Audit Committee Chair to member).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, or specific risk factors beyond standard securities law disclosures regarding the unregistered nature of the granted options. The company notes that the securities may not be offered or sold absent registration or an exemption.
Investor Verification Checklist
- Verify the total number of outstanding options and the impact of the 965,000 new grants on potential dilution.
- Confirm the vesting schedules and exercise prices for the options granted to Blair Jordan, Ryan Smith, Stephen H. Shoemaker, Dr. Lawrence Steinman, and Eric R. Van Lent.
- Review the updated composition of the Audit and Compensation Committees to assess governance independence.
- Check for any subsequent filings regarding the exercise of these options or changes in executive compensation.